{"id":862,"date":"2014-01-17T15:10:16","date_gmt":"2014-01-17T15:10:16","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=862"},"modified":"2014-01-18T13:54:35","modified_gmt":"2014-01-18T13:54:35","slug":"langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/","title":{"rendered":"Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid"},"content":{"rendered":"<p>AMB 2013,\u00a047, 71a &nbsp; Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid &nbsp; Fazit: Der 5-alpha-Reduktasehemmer Finasterid verringert bei M\u00e4nnern mit Benigner Prostatahypertrophie und besonders gro\u00dfer Prostata die Morbidit\u00e4t und das Risiko, an der Prostata operiert werden zu m\u00fcssen. Bei dieser Indikation f\u00fcr Finasterid kann man die &#8230;\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2013,\u00a047, 71a &nbsp; Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid &nbsp; Fazit: Der 5-alpha-Reduktasehemmer Finasterid verringert bei M\u00e4nnern mit Benigner Prostatahypertrophie und besonders gro\u00dfer Prostata die Morbidit\u00e4t und das Risiko, an der Prostata operiert werden zu m\u00fcssen. Bei dieser Indikation f\u00fcr Finasterid kann man die &#8230;\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[24,33],"tags":[151,273,276,274,275,277],"class_list":["post-862","post","type-post","status-publish","format-standard","hentry","category-jahr-2013-band-47","category-monat-09","tag-finasterid","tag-pcpt-studie","tag-prostata-spezifisches-antigen","tag-prostatahyperplasie","tag-prostatakarzinom","tag-psa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid<\/title>\n<meta name=\"description\" content=\"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\" \/>\n<meta property=\"og:description\" content=\"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-01-17T15:10:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-01-18T13:54:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\",\"datePublished\":\"2014-01-17T15:10:16+00:00\",\"dateModified\":\"2014-01-18T13:54:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/\"},\"wordCount\":292,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Finasterid\",\"PCPT-Studie\",\"Prostata-spezifisches Antigen\",\"Prostatahyperplasie\",\"Prostatakarzinom\",\"PSA\"],\"articleSection\":[\"Jahr 2013 Band 47\",\"Monat 09\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/\",\"name\":\"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-01-17T15:10:16+00:00\",\"dateModified\":\"2014-01-18T13:54:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","description":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/","og_locale":"de_DE","og_type":"article","og_title":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","og_description":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-01-17T15:10:16+00:00","article_modified_time":"2014-01-18T13:54:35+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","datePublished":"2014-01-17T15:10:16+00:00","dateModified":"2014-01-18T13:54:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/"},"wordCount":292,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Finasterid","PCPT-Studie","Prostata-spezifisches Antigen","Prostatahyperplasie","Prostatakarzinom","PSA"],"articleSection":["Jahr 2013 Band 47","Monat 09"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/","name":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-01-17T15:10:16+00:00","dateModified":"2014-01-18T13:54:35+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Finasterid: Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/langzeitergebnisse-des-prostate-cancer-prevention-trial-mit-finasterid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Langzeitergebnisse des \u201eProstate Cancer Prevention Trial\u201c mit Finasterid"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=862"}],"version-history":[{"count":7,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/862\/revisions"}],"predecessor-version":[{"id":964,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/862\/revisions\/964"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}